Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: A phase I trial

48Citations
Citations of this article
110Readers
Mendeley users who have this article in their library.

Abstract

Human Natural Killer (NK) cells require at least two signals to trigger tumor cell lysis. Absence of ligands providing either signal 1 or 2 provides NK resistance. We manufactured a lysate of a tumour cell line which provides signal 1 to resting NK cells without signal 2. The tumor-primed NK cells (TpNK) lyse NK resistant Acute Myeloid Leukemia (AML) blasts expressing signal 2 ligands. We conducted a clinical trial to determine the toxicity of TpNK cell infusions from haploidentical donors. 15 patients with high risk AML were screened, 13 enrolled and 7 patients treated. The remaining 6 either failed to respond to re-induction chemotherapy or the donor refused to undergo peripheral blood apheresis. The conditioning consisted of fludarabine and total body irradiation. This was the first UK trial of a cell therapy regulated as a medicine. The complexity of Good Clinical Practice compliance was underestimated and led to failures requiring retrospective independent data review. The lessons learned are an important aspect of this report. There was no evidence of infusional toxicity. Profound myelosuppression was seen in the majority (median neutrophil recovery day 55). At six months follow-up, three patients treated in Complete Remission (CR) remained in remission, one patient infused in Partial Remission had achieved CR1, two had relapsed and one had died. One year post-treatment one patient remained in CR. Four patients remained in CR after treatment for longer than their most recent previous CR. During the 2 year follow-up six of seven patients died; median overall survival was 400 days post infusion (range 141-910). This is the first clinical trial of an NK therapy in the absence of IL-2 or other cytokine support. The HLA-mismatched NK cells survived and expanded in vivo without on-going host immunosuppression and appeared to exert an anti-leukemia effect in 4/7 patients treated.

References Powered by Scopus

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

1561Citations
N/AReaders
Get full text

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population

956Citations
N/AReaders
Get full text

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

659Citations
N/AReaders
Get full text

Cited by Powered by Scopus

NK cells for cancer immunotherapy

839Citations
N/AReaders
Get full text

NK cell-based immunotherapy for cancer

260Citations
N/AReaders
Get full text

The rise of allogeneic Natural killer cells as a platform for cancer immunotherapy: Recent innovations and future developments

156Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kottaridis, P. D., North, J., Tsirogianni, M., Marden, C., Samuel, E. R., Jide-Banwo, S., … Lowdell, M. W. (2015). Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: A phase I trial. PLoS ONE, 10(6). https://doi.org/10.1371/journal.pone.0123416

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 27

44%

Researcher 19

31%

Lecturer / Post doc 10

16%

Professor / Associate Prof. 6

10%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 16

29%

Medicine and Dentistry 15

27%

Immunology and Microbiology 13

24%

Pharmacology, Toxicology and Pharmaceut... 11

20%

Save time finding and organizing research with Mendeley

Sign up for free